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ABSTRACT
The heritability of lifespan is 20-30%, but only a few genes associated with 
longevity have been identified. To explain this discrepancy, the inheritance of 
epigenetic features, such as DNA methylation, have been proposed to contribute to 
the heritability of lifespan.
We investigated whether parental lifespan is associated with DNA methylation 
profile in nonagenarians. A regression model, adjusted for differences in blood cell 
proportions, identified 659 CpG sites where the level of methylation was associated 
with paternal lifespan. However, no association was observed between maternal 
lifespan and DNA methylation. The 659 CpG sites associated with paternal lifespan 
were enriched outside of CpG islands and were located in genes associated with 
development and morphogenesis, as well as cell signaling. The largest difference 
in the level of methylation between the progeny of the shortest-lived and longest-
lived fathers was identified for CpG sites mapping to CXXC5. In addition, the level 
of methylation in three Notch-genes (NOTCH1, NOTCH3 and NOTCH4) was also 
associated with paternal lifespan.
There are implications for the inheritance of acquired traits via epigenetic 
mechanisms in mammals. Here we describe DNA methylation features that are 
associated with paternal lifespan, and we speculate that the identified CpG sites may 
represent intergenerational epigenetic inheritance.
INTRODUCTION
The heritability of lifespan (age at death) has been 
estimated to be approximately 20-30%, and it has been 
shown to increase with advancing age. Healthy aging is 
also heritable, and the offspring of long-lived parents show 
delayed onset of aging-associated diseases [1, 2, 3, 4]. 
Much of the research studying the heritability of lifespan 
has focused on extreme age (nonagenarians, centenarians, 
supercentenarians), but recently it has been shown that 
every decade of parental age after the age of 65 reduces 
the mortality and incidence of cancer of their offspring [5].
Even though the heritability of the lifespan is 
acknowledged, only one genomic locus (on chromosome 
3) and a few genetic variants, such as in APOE and
FOXO3, have consistently been shown to be associated 
with longevity. Data regarding other genomic loci and 
genes, including CETP, HSF2 and MTP, have been 
inconsistent between studies [3]. Therefore, in addition 
to disease susceptibility alleles, rare genetic variants 
and environment-genome interactions, epigenetic 
mechanisms such as DNA methylation may be mediating 
the heritability of lifespan. 
Changes in DNA methylation are associated with 
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aging and many aging-associated diseases, such as 
cancer, Alzheimer’s disease and type 2 diabetes [6]. These 
changes include global hypomethylation and site-specific 
hypermethylation [7, 8, 9], and both tightly regulated and 
environmental or stochastic effects have been reported 
[10, 11, 12]. Aging-associated hypomethylation has been 
shown to be delayed in the offspring of centenarians [13].
The role of transgenerational epigenetic inheritance 
in the heritability of acquired traits has been discussed 
in the literature. In mice and rats, there is evidence that 
environmental exposure (for example, to vinclozolin and 
ethanol) causes phenotypic effects and changes in somatic 
and sperm DNA methylation, and these effects have been 
shown to be transmitted to the F4 generation [14, 15, 
16, 17]. In a majority of the studies, the inheritance of 
epigenetic features is affected by the sex of the parent or 
progeny [15, 16, 18].
In humans, the environmental conditions 
experienced during early childhood or fetal development 
have been shown to link to epigenetic features, typically 
DNA methylation, in adulthood. For example, the 
progeny of mothers who experienced famine during 
early pregnancy are more prone to obesity and raised 
blood lipids, and the methylation status of the IGF2 
gene is affected in these progeny [19, 20]. In addition, 
childhood abuse has been associated with alterations 
to DNA methylation in middle-aged men [21]. In some 
cases, the environmental factors (e.g. nutrition, tobacco 
smoking, and betel quid chewing) experienced by fathers 
or grandfathers have been shown to affect the phenotype 
of their sons or grandsons (e.g. increased risk of diabetic 
death and increased adiposity). It is suspected that these 
traits are inherited via epigenetic mechanisms [18]. 
The effect of length of parental lifespan on the DNA 
methylation profile of progeny has not been previously 
studied. Here, we sought to identify DNA methylation 
patterns that are associated with maternal or paternal 
lifespan (age at death) to determine whether this trait 
manifests in the DNA methylome of progeny. DNA 
methylation profiles that are common among the progeny 
of longer-living parents may be components that are 
partially responsible for the heritability of lifespan.
RESULTS
Long-living fathers, long-living siblings
The study population consisted of 90 nonagenarians 
who participated in the Vitality 90+ study cohort of 2010 
[8, 22]. In the regression model used to identify CpG sites 
associated with parental age, parental age was used as a 
continuous variable. However, for group comparisons, 
the population was divided into three groups according 
to paternal (FI (shortest-living fathers), FII, FIII (longest-
living fathers)) and maternal age (MI (shortest-living 
mothers), MII, MIII (longest-living mothers)). See Table 
1 for distribution of parental ages.
We found that group FIII (progeny of the longest-
living fathers) had more long-living siblings (siblings 
living over 85 years) compared to group FI (Mann-
Whitney U-test p = 0.004). This difference remains 
statistically significant when considering siblings over 75 
years (p = 0.006) or siblings over 80 years (p = 0.006). 
The lifespan of the mother had no effect on the number 
of long-living siblings (comparison between groups MIII 
and MI: for siblings over 85 years of age, p = 0.148, for 
siblings over 80 years, p = 0.338 and for siblings over 75 
years, p = 0.242). 
Paternal lifespan was not correlated with maternal 
lifespan (Spearman’s rho = 0.159, p = 0.135) or with 
paternal age at conception (data on paternal age at 
conception available only for a subset of the population 
(n = 21), Spearman’s rho = -0.252, p = 0.271). In addition, 
paternal lifespan was not associated with the socio-
economic status of offspring.
Association of paternal age with DNA methylation 
profile
The DNA methylation profile was determined with 
Illumina Infinium HumanMethylation450 BeadChip from 
peripheral blood mononuclear cells. We identified 659 
CpG sites where the level of methylation was associated 
Table 1: Grouping of study population according to paternal and maternal lifespan. 
n Age of father at death Age of mother at death
Whole population 90 40-103 (67) 40-101 (79.5)
Group FI 32 40-60 (55)
Group FII 30 61-75 (67.5)
Group FIII 28 77-103 (83)
Group MI 32 40-72 (58)
Group MII 32 75-83 (80)
Group MIII 26  84-101 (88.5)
For group comparisons, the population was divided according to paternal and maternal 
lifespan. Presented here are the age range and (median) age at death for fathers and mothers.
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Table 2: Genes with the largest number of CpG sites associated with paternal lifespan. 
n(CpG) ID p-value (BH-corrected) Δβ














BID 3 cg03433260 0.042 -0.017
cg20234121 0.044 -0.014
cg01280609 0.025 -0.013
FGR 3 cg09845000 0.029 -0.046
cg09370867 0.030 -0.046
cg13448978 0.046 -0.042
LOC283050 3 cg24658487 0.021 -0.041
cg22890825 0.046 -0.035
cg06891775 0.049 -0.018
In total, 42 genes harbored more than one affected CpG site (see Supplementary Table 2) 
and 6 genes contained three or more CpG sites associated with paternal lifespan. Δβ refers 
to the difference in methylation level between group FIII and group FI.
Figure 1: Location of CpG sites associated with paternal lifespan and methylation level of CXXC5. A. Location of 
CpG sites associated with paternal lifespan with regard to CpG islands. There were fewer than expected CpG sites found in CpG islands 
(hypergeometric test p < 0.05). B. Differences in the level of methylation in CXXC5. Level of methylation in each CpG site is presented for 
each group (Group I, progeny of shortest-lived fathers, Group III, progeny of longest-lived fathers).
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with paternal lifespan (regression model p-value < 0.05 
(BH-corrected), Δβ between group FIII and FI >1%, see 
Supplementary Table 1). Of the CpG sites associated 
with paternal lifespan, higher paternal age was associated 
with decreasing level of methylation in 423 (64%). There 
were no CpG sites where the level of methylation was 
associated with maternal lifespan. It is noteworthy that 
both the number of long-living siblings and the DNA 
methylation profile were associated with paternal lifespan, 
but not with maternal lifespan.
The CpG sites that were associated with paternal 
age were not enriched in any particular chromosome or 
gene location (hypergeometric test p>0.05). However, 
there were fewer than expected CpG sites in CpG islands 
(hypergeometric test p < 0.05, see Figure 1A).
Because a small number of DNA methylation 
changes in key genes that are involved in a given 
biological process can regulate the whole process or 
pathway (without DNA methylation changes to other 
genes), we wanted to investigate the identified top hits 
more closely. We defined the top hits as CpG sites with 
>5% difference in Δβ between groups FIII and FI or CpG 
sites that were located in a gene that harbored at least two 
CpG sites associated with paternal age. There were 65 
CpG sites located in 46 different genes with Δβ>5%, and 
31 additional genes had at least two CpG sites that were 
associated with paternal lifespan. Combined, there were 
146 CpG sites and 77 genes that were further characterized 
(Supplementary Table 2). Among all CpG sites associated 
with paternal age, there were more sites where the level 
of methylation decreased as paternal age increased. This 
trend was even more pronounced among the top hits, 
where 116 out of 146 sites (79%) showed decreasing 
methylation levels with increasing paternal age.
CXXC5 (CXXC finger protein 5) was the most 
affected gene, harboring 6 CpG sites where the level of 
methylation was associated with paternal lifespan, and in 
all of these CpG sites, higher paternal age was associated 
with a decreased level of DNA methylation (Figure 1B). 
All genes with 3 or more CpG sites associated with paternal 
age are presented in Table 2. The largest Δβ between group 
FIII and group FI were observed at cg19628988 (CXXC5, 
Δβ = -0.082), cg12076931 (NOTCH1, Δβ = -0.080), 
cg23644389 (Δβ = 0.072) and cg24607398 (EPM2AIP1, 
Δβ = 0.069) (Table 3). In addition to NOTCH1, NOTCH4 
also included a CpG site with a Δβ>5% (cg06023661, Δβ 
= -0,066) and both genes harbored an additional CpG site 
(in NOTCH1, cg13861904, Δβ = -0.042 and in NOTCH4, 
cg06815976, Δβ = -0.042). NOTCH3 also harbored two 
CpG sites where the level of methylation was associated 
with paternal lifespan (cg27320207, Δβ = -0.038 and 
cg26880200, Δβ = 0.020).
Table 3: CpG sites associated with paternal lifespan that had the largest 
Δβ between group FIII and group FI. 
Gene ID p-value (BH-corrected) Δβ
CXXC5 cg19628988 0.048 -0.082
NOTCH1 cg12076931 0.032 -0.080
KRT27 cg10747531 0.032 -0.077
na cg11284147 0.047 -0.077
CXXC5 cg15165154 0.023 -0.072
MPZL1 cg04846203 0.035 -0.067
NOTCH4 cg06023661 0.038 -0.066
UEVLD cg15846482 0.033 -0.065
SORT1 cg02175308 0.028 -0.065
DAP cg14129473 0.032 -0.064
MORC2 cg23825480 0.047 0.055
RRAD cg06410849 0.032 0.056
RESP18 cg19020434 0.032 0.057
ITPKB cg23717186 0.037 0.059
na cg00248242 0.041 0.059
CPA5 cg22664614 0.039 0.059
na cg14828411 0.040 0.060
GULP1 cg16947583 0.034 0.062
EPM2AIP1 cg24607398 0.023 0.069
na cg23644389 0.045 0.072
For all CpG sites associated with paternal lifespan, see Supplementary Table 
1. na = no gene annotation available.
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Pathways
The 659 CpG sites associated with paternal lifespan 
were located in 422 different genes. Cellular processes 
and signaling pathways associated with the identified 
genes were searched using QIAGEN’s Ingenuity® pathway 
analysis (IPA) [23] and GOrilla [24,25]. We identified only 
one canonical pathway, B cell receptor signaling, that was 
associated with the identified genes when p-values were 
corrected for multiple testing (BH-corrected p-value < 
0.05). Using GO term analysis, we identified 35 enriched 
GO process terms (BH-corrected p-value < 0.05) that 
were associated with genes harboring the CpG sites that 
were associated with paternal lifespan. The identified 
GO process terms were associated with development and 
morphogenesis and with cell signaling (Table 4).
In the GO term analysis for the top hits, no term 
reached multiple testing-corrected statistical significance 
(BH-corrected p-value < 0.05), but there was a trend 
toward developmental and signaling processes. Similarly, 
no significant canonical pathways were identified when 
multiple testing correction was used (BH-corrected 
p-value < 0.05). However, Notch-signaling was closest to 
the significance threshold (BH-corrected p-value = 0.084). 
Table 4: GO process terms associated with genes where methylation level is associated with paternal lifespan. 
GO Term Description p-value (BH-corrected)
GO:0048523 negative regulation of cellular process 0.011
GO:0010646 regulation of cell communication 0.012
GO:0022603 regulation of anatomical structure morphogenesis 0.013
GO:0023051 regulation of signaling 0.014
GO:0040012 regulation of locomotion 0.016
GO:0044767 single-organism developmental process 0.016
GO:0009966 regulation of signal transduction 0.017
GO:0032502 developmental process 0.019
GO:0048519 negative regulation of biological process 0.022
GO:0030154 cell differentiation 0.022
GO:0009653 anatomical structure morphogenesis 0.024
GO:0051270 regulation of cellular component movement 0.024
GO:0050878 regulation of body fluid levels 0.024
GO:0050794 regulation of cellular process 0.025
GO:2000147 positive regulation of cell motility 0.025
GO:0044707 single-multicellular organism process 0.025
GO:0031325 positive regulation of cellular metabolic process 0.025
GO:0040017 positive regulation of locomotion 0.026
GO:0051239 regulation of multicellular organismal process 0.026
GO:0007165 signal transduction 0.026
GO:0090527 actin filament reorganization 0.026
GO:0048583 regulation of response to stimulus 0.026
GO:0009893 positive regulation of metabolic process 0.026
GO:0048522 positive regulation of cellular process 0.027
GO:0048856 anatomical structure development 0.027
GO:0030335 positive regulation of cell migration 0.027
GO:0051272 positive regulation of cellular component movement 0.028
GO:0048869 cellular developmental process 0.028
GO:0048518 positive regulation of biological process 0.029
GO:0032501 multicellular organismal process 0.030
GO:0007596 blood coagulation 0.032
GO:0050817 coagulation 0.033
GO:0007599 hemostasis 0.034
GO:0050789 regulation of biological process 0.035
GO:0065007 biological regulation 0.047
The 659 CpG sites associated with paternal lifespan were located in 422 different genes, and these genes were enriched to 35 
GO process terms (Benjamini-Hochberg multiple testing corrected p-value of < 0.05).
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DISCUSSION
Here, we report the identification of 659 CpG sites 
where the level of methylation was associated with length 
of paternal lifespan. These results were adjusted for 
differences in blood cell type percentages. We speculate 
that these sites may represent intergenerational epigenetic 
inheritance and that these methylation sites could be 
associated with heritability of lifespan.
Cell signaling
CXXC5, a member of the small zinc finger 
protein family, contained 6 CpG sites where the level 
of methylation decreased as paternal lifespan increased. 
CXXC5 negatively regulates Wnt/β-catenin signaling [26, 
27, 28] and has been shown to be a mediator in BMP-
signaling [29]. CXXC5 has a role in normal and tumoral 
myelopoiesis [30] and in endothelial cell differentiation 
and migration and vessel formation [29]. The CXXC motif 
recognizes unmethylated CpG sites, and these proteins are 
involved in epigenetic modifications [31].
Six CpG sites in three Notch genes (NOTCH1, 3 and 
4) were associated with paternal lifespan in our study. In 
addition, pathway analyses implied that Notch-signaling 
is associated with DNA methylation changes that are 
associated with paternal lifespan. The Notch-signaling 
pathway functions in various cell types and at various 
time points during development. Notch-signaling plays a 
role in development and organogenesis, and also in adult 
tissue maintenance and repair [32]. Notch-signaling has 
been associated with aging associated loss of muscle mass 
and function (sarcopenia). Impairments in Notch-signaling 
may be responsible for loss of myogenic potential in aged 
muscle. This association may also be due to an imbalance 
in Notch- and Wnt-signaling [32, 33, 34]. In addition, 
disruptions in Notch-signaling have been implicated in 
certain cancers and associated with Alzheimer’s disease 
[32].
GO term analysis showed that signaling was 
affected, and B cell receptor signaling was also specifically 
identified as being associated with the identified genes in 
our study. In parallel with other changes in the immune 
system, the B cell pool goes through various changes 
during aging, and some of these changes have also been 
associated with adverse health outcomes [35, 36]. Our 
results imply that these changes can be partially regulated 
by DNA methylation. However, because we were unable 
to adjust the analysis for the proportion of B cells, this 
result may be due to differences in B cell proportions 
across study samples.
A previous study showed that genes that are 
hypomethylated in the offspring of nonagenarians 
(compared to progeny of non-long-lived parents) were 
also associated with signal transmission [13], and our own 
results show that GO process terms, such as regulation 
of cell communication (GO:0010646) and regulation of 
signaling (GO:0023051), are associated with genes that 
contain methylation sites where the level of methylation 
is associated with paternal lifespan (Table 4). A review by 
Carlson et al. [32] discussed the association between aging 
and changes in signaling intensities in various signaling 
pathways (for example Notch-, TGFβ- and Wnt-signaling). 
These pathways function in an intertwined network, and 
proper regulation is needed to balance signaling during 
development and adult tissue maintenance and repair. 
 Location of CpGs associated with paternal age
Of the identified CpG sites associated with paternal 
lifespan, fewer were located in CpG-dense CpG islands 
than expected. They were instead enriched outside of CpG 
islands and in shores and shelves. It has been shown, in 
mice, that methylation level is associated with paternal 
environmental effects at CpG sites that are located in 
low-CG areas of the genome [37]. DNA methylation at 
CpG islands, and particularly at transcription start sites, 
is usually considered to be the more important regulator 
of gene expression [38], but the CpG-poor regions of the 
genome have also recently been proposed to be important 
for regulation [39, 40].
Aging and longevity are linked with development
We found that methylation sites that were associated 
with paternal lifespan were enriched in genes associated 
with development and morphogenesis. Aging associated 
hypermethylation has also been shown to be enriched in 
genes associated with development and morphogenesis [8, 
13, 41, 42, 43].
The roles of developmental or metabolic rates in 
aging and longevity have been extensively studied, and 
caloric restriction, body size, changes in insulin signaling 
and the mTOR-pathway also have implied associations 
with longevity [44, 45, 46]. Alterations in the epigenetic 
mechanisms that control developmental processes may 
also contribute to lifespan. The role of developmental 
programs in aging is also a component of the quasi-
programmed hyperfunction theory of aging, which states 
that aging is the aimless continuation of a developmental 
program when it is no longer needed [47]. Because these 
developmental programs are needed early in life, large 
alterations to these pathways would likely be deleterious. 
Thus, we expect that the DNA methylation changes 
identified in this study have only small effects on lifespan.
Oncotarget30563www.impactjournals.com/oncotarget
Mechanism of epigenetic inheritance
Both human and mouse studies have implied 
that certain traits acquired by a parent can be inherited 
by progeny, at least for one or two generations, and 
that some of these cases involve DNA methylation (see 
Introduction). The molecular mechanism explaining how 
inheritance through DNA methylation patterns occurs is 
still lacking, because the DNA methylome goes through 
two major reprogramming steps, first in the embryo and 
then in primordial germ cells [15, 48]. However, imprinted 
genes do have parent-of-origin-dependent expression 
patterns [49], and it has recently been shown that in 
mice, certain genomic regions at least partially avoid 
the reprogramming of the DNA methylome [50, 51]. 
Thus, transgenerational epigenetic inheritance is at least 
plausible in humans.
The DNA methylation features associated with 
paternal lifespan that were identified in this study may be 
intergenerationally inherited. However, we cannot exclude 
that the hereditary component may be another epigenetic 
feature, rather than DNA methylation, or traditional 
genetic element that contributes to the perceived DNA 
methylation pattern. 
Both transgenerational epigenetic inheritance 
and the heritability of longevity and lifespan appear to 
be dependent on the sex of the parent and/or progeny, 
although reported results are inconsistent in the case 
of longevity and lifespan [5]. Our results show that the 
DNA methylation landscape and the number of longer-
living siblings are associated only with paternal, and not 
maternal, lifespan. Our results therefore support the notion 
that there are sex differences in the heritability of lifespan. 
Due to the small study population, we were unable to 
identify the effects of paternal lifespan on the DNA 
methylome of daughters and sons separately, although 
sex was included as a covariate in the regression model. 
There is a female advantage in longevity, and females 
have better survival at all ages. Various mechanisms, 
including hormonal effects and differences in immune 
function (role of estrogen and androgens, susceptibility to 
infections [52,53]) as well as the role of X chromosome 
(skewing of X chromosome inactivation [54]) have been 
speculated to play a role, but definitive proof is lacking. 
Similarly, sexual dimorphism in the heritability of factors 
contributing to lifespan remain to be speculated [55]. 
Our results also indicate that paternal lifespan is not 
associated with the socio-economic status of the progeny, 
suggesting that this observed effect is not due to a shared 
environment.
CONCLUSIONS
In summary, we show that length of paternal lifespan 
is associated with progeny DNA methylation profiles and 
that this effect can be identified in nonagenarians. To our 
knowledge, the effects of the full range of parental lifespan 
on DNA methylation have not been previously analyzed. 
However, Gentilini et al. [13] did study the effect of 
extreme longevity in women. The methylation sites 
associated with paternal lifespan reported in the current 
study were located in genes associated with development 
and morphogenesis, as well as cell signaling. These 
results imply that these processes may be epigenetically 
regulating lifespan.
These results suggest that part of the “missing” 
heritability of lifespan may be epigenetic in nature. In 
addition to epigenetics, rare genetic variants most likely 
contribute to the heritability of lifespan. Because the length 
of lifespan is also significantly affected by environmental 
effects, lifestyle factors and interaction effects between 
environment and genetics, further studies are needed to 
uncover the genetic and epigenetic features that provide 
minor contributions to the heritability of lifespan.
 MATERIALS AND METHODS
Study population
The study population consisted of 90 individuals 
born in 1920 (females n = 66, males n = 24) who 
participated in the home examinations in the Vitality 
90+ Study in the year 2010. The study subjects included 
in this study were selected from the Vitality 90+ study 
cohort of 2010 based on two criteria: (i) information 
on both maternal and paternal lifespan was available 
and (ii) both parents had a lifespan of 40 years or more. 
The Vitality 90+ study is an on-going, prospective, 
population based study that includes both home dwelling 
and institutionalized individuals who are aged 90 years 
or more, and who live in the city of Tampere, Finland. 
The recruitment and characterization of participants 
were performed as has been reported in earlier Vitality 
90+ study cohorts [22]. The study subjects were all of 
Western European descent and had not had any infections 
or received any vaccinations in the 30 days prior to blood 
sample collection. The study participants provided their 
written informed consent. This study was conducted 
according to the principles expressed in the declaration 
of Helsinki, and the study protocol was approved by the 
ethics committee of the city of Tampere (1592/403/1996).
Sample collection
Blood samples were collected into EDTA-containing 
tubes by a trained medical student during a home visit. 
All blood samples were drawn between 8 am and 12 am. 
Samples were directly subjected to leucocyte separation on 
a Ficoll-Paque density gradient (Ficoll-Paque™ Premium, 
Oncotarget30564www.impactjournals.com/oncotarget
cat. no. 17-5442-03, GE Healthcare Bio-Sciences AB, 
Uppsala, Sweden). The PBMC layer was collected and 
was suspended in 1 ml of a freezing solution (5/8 FBS, 
2/8 RPMI-160 medium, 1/8 DMSO) (FBS cat. no. F7524, 
Sigma-Aldrich, MO, USA; RPMI: cat. no. R0883, Sigma-
Aldrich, MO, USA; DMSO: cat. no. 1.02931.0500, VWR, 
Espoo, Finland) and stored in liquid nitrogen.
Information on the age of death of parents and 
siblings and the age of living siblings was collected with a 
questionnaire at the home visit.
DNA extraction
DNA was extracted from PBMCs using the 
QIAamp DNA Mini kit (Qiagen, CA, USA), following 
the manufacturer’s instructions for the spin protocol. The 
DNA was eluted in 60 μl of AE elution buffer and stored 
at -20°C. The concentration and quality of the DNA was 
assessed with the Qubit dsDNA HS Assay (Invitrogen, 
Eugene, OR, USA).
FACS
The proportions of different lymphocyte populations 
were determined through FACS analysis (BD FACSCanto 
II), and the results were analyzed with BD FACS Diva, 
version 6.1.3 (BD Biosciences, Franklin Lakes, NJ, USA). 
The antibodies employed in this analysis were FITC-CD14 
(cat. no. 11-0149), PerCP-Cy5.5-CD3 (45-0037), APC-
CD28 (17-0289) (eBioscience, San Diego, CA, USA), 
PE-Cy™7-CD4 (cat. no. 557852) and APC-Cy™7-CD8 
(557834) (BD Biosciences).
Methylation array
Genome-wide DNA methylation profiling was 
performed at the Institute for Molecular Medicine 
Finland (FIMM) Technology Centre of the University of 
Helsinki in two batches (time interval, 6 months). Bisulfite 
conversion of 1 µg of DNA was performed using an EZ-
96 DNA Methylation Kit (Zymo Research, Irvine, CA, 
USA) according to the manufacturer’s instructions. A 4 µl 
aliquot of bisulfite-converted DNA was subjected to whole 
genome amplification and then enzymatically fragmented 
and hybridized to the Infinium HumanMethylation450 
BeadChip (Illumina, San Diego, CA, USA) according to 
the manufacturer’s protocol. Samples were assigned to 
the arrays in a randomized order. The BeadChips were 
scanned using an iScan reader (Illumina).
Processing of the methylation data
The data were processed as described previously [8], 
and can be accessed in GEO database (GSE58888) [56]. 
Before any processing, all unspecific or polymorphic sites 
(n = 76775) with minor allele frequency higher than 5%, 
based on database information [57], and probes mapping to 
sex chromosomes (n = 11 648) were removed. Methylation 
data were preprocessed as a methylumiset object using 
R software (R> = 2.15.3) with the wateRmelon array-
specific package [58]. Technically poor quality samples 
and target sites were filtered out by excluding sites with 
a beadcount of < 3 in 5% of the samples (n = 515) and 
sites for which 1% of the samples had a detection p-value 
> 0.05 (n = 698). Background correction and quantile 
normalization were conducted individually for the two 
chemistries (Infinium I and II) as well as for the intensities 
of methylation (m) and un-methylation (u) using the dasen 
method. After dasen normalization, the u and m intensities 
were transformed to values of beta (β). β is the ratio of 
methylated probe (m) intensities to overall intensities 
(m+u+α), where α is the constant offset, 100. Thus, β 
ranges linearly between 0 (non-methylated, 0%) and 1 
(completely methylated, 100%). Next, the batch effect of 
the Infinium chemistries was adjusted using the BMIQ 
algorithm, which is based on beta mixture-models and the 
EM-algorithm [59]. Several visualization styles were used 
to verify the quality of the data, including boxplots from 
the raw intensities, Kernel density plots in the chemistry 
correction procedure and PCA (principal component 
analysis). 
Detection of methylation sites associated with 
parental age
To assess the relationship between site-specific 
methylation level and the age of the father/mother at the 
time of death, a generalized regression model, referred to 
as variable dispersion beta regression [60, 61], was utilized 
on each CpG site. The age of the father and mother at the 
time of death (linear variable) and the gender (categories 
0 and 1) of the subject were employed as predictors of 
the site-specific methylation outcome in the form of 
β-values (ranging from 0 to 1) in each equation, where the 
mean model with a linker function of logit was utilized. 
Furthermore, as was previously observed, because 
methylation levels fluctuate based on the composition of 
blood cell subtypes [8,62], the variables corresponding to 
cell type proportions (the CD4+ to CD8+ ratio and the 
proportions of CD28/CD4+ and CD28-/CD8+ and CD14+ 
cells) were included as linear covariates in the model. 
The bias caused by the batch effect of two laboratory 
days (time interval of 6 months) was also confirmed by 
PCA. Therefore, a variable corresponding to the batches 
(categories 0 and 1) was set as covariate in the model. The 
nominal Benjamini-Hochberg corrected p-value was set 
to 0.05. Next, the CpG sites with substantial differences 
in methylation level between the extreme age groups were 
extracted. The subjects were categorized to groups FI, FII, 
Oncotarget30565www.impactjournals.com/oncotarget
FIII (and MI, MII, MIII), with equal group sizes according 
to the age of the father/mother at the time of death (see 
Table 1). The extraction procedure was conducted by 
calculating the difference in median values of methylation 
in each CpG site for groups I and III, and only sites with 
-0.01>Δβ>0.01 were included for further analysis. 
Pathway analyses
Pathway analyses were performed on genes 
harboring CpG sites where the level of methylation was 
associated with paternal lifespan. The 659 CpG sites were 
located in 422 different genes.
IPA [23] was used to identify canonical pathways 
associated with the identified genes. According to 
the manufacturer, these canonical pathways are well 
characterized metabolic and cell signaling pathways 
that have been curated and hand-drawn by PhD-level 
scientists. All of the data sources provided by the 
Ingenuity Knowledge Base were included in the IPA, and 
the Ingenuity Knowledge Base was used as the reference 
set in all analyses. For the association of molecules, only 
experimentally observed results were accepted, and only 
human data were considered. A Benjamini-Hochberg 
multiple testing corrected p-value of < 0.05 was used 
as the threshold for significance. The Ingenuity pathway 
analysis was performed on the 12th of March 2015.
GOrilla [24, 25] was used to identify the enriched 
GO terms for the identified genes. GO terms were searched 
based on two unranked lists (target and background), 
and all genes with at least one probe in the 450K array 
were used as the background list. A Benjamini-Hochberg 
multiple testing corrected p-value of < 0.05 was used 
as the threshold for significance. GOrilla analysis was 
performed on the 29th of April 2015.
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